Goldman Sachs Group Inc. Has $1.33 Million Stake in Dianthus Therapeutics, Inc. $DNTH

Goldman Sachs Group Inc. cut its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 64.7% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 73,430 shares of the company’s stock after selling 134,637 shares during the period. Goldman Sachs Group Inc. owned about 0.23% of Dianthus Therapeutics worth $1,332,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Octagon Capital Advisors LP boosted its stake in shares of Dianthus Therapeutics by 11.0% during the 1st quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company’s stock valued at $42,478,000 after buying an additional 231,500 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after purchasing an additional 618 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its stake in Dianthus Therapeutics by 5.0% in the first quarter. Adage Capital Partners GP L.L.C. now owns 189,000 shares of the company’s stock valued at $3,428,000 after purchasing an additional 9,000 shares in the last quarter. ADAR1 Capital Management LLC increased its position in Dianthus Therapeutics by 3.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company’s stock worth $332,000 after purchasing an additional 602 shares during the last quarter. Finally, Vestal Point Capital LP increased its position in Dianthus Therapeutics by 58.1% in the 1st quarter. Vestal Point Capital LP now owns 1,700,069 shares of the company’s stock worth $30,839,000 after purchasing an additional 625,069 shares during the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of the business’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total value of $700,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 8.15% of the stock is currently owned by company insiders.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock opened at $36.75 on Friday. The company has a market capitalization of $1.18 billion, a PE ratio of -11.31 and a beta of 1.46. Dianthus Therapeutics, Inc. has a one year low of $13.36 and a one year high of $39.87. The business has a 50 day simple moving average of $24.83 and a 200 day simple moving average of $21.12.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.87 million. Equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DNTH has been the topic of several research reports. Raymond James Financial reaffirmed an “outperform” rating and issued a $63.00 target price (up from $56.00) on shares of Dianthus Therapeutics in a research report on Tuesday, September 9th. William Blair began coverage on shares of Dianthus Therapeutics in a research note on Wednesday, July 2nd. They issued an “outperform” rating for the company. Robert W. Baird lifted their target price on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the company an “outperform” rating in a research note on Tuesday, September 9th. Wedbush lifted their target price on shares of Dianthus Therapeutics from $42.00 to $44.00 and gave the company an “outperform” rating in a research note on Friday, September 12th. Finally, Guggenheim raised their price target on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, September 9th. Nine research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $61.57.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.